# Methylfolate (5-MTHF)

> Methylfolate (5-MTHF) is the bioactive form of folate that bypasses MTHFR genetic blocks. Since around 85% of hEDS patients carry an MTHFR variant, standard folic acid often won't convert efficiently. Methylfolate also regulates MMPs that degrade collagen and supports neurotransmitter synthesis. ZebraThrive uses 800 mcg daily in the AM stack.

**Page:** https://www.wellnessforzebras.com/ingredients/methylfolate
**Brand:** ZebraThrive
**Author:** Ken Chapman, Founder of ZebraThrive
**Last reviewed:** 2026-05-11
**Daily dose:** 800 mcg daily (AM capsules)
**Form used:** (6S)-5-MTHF glucosamine salt (Quatrefolic-equivalent spec)
**Target population:** Adults 18+ with hypermobile Ehlers-Danlos Syndrome (hEDS), Postural Orthostatic Tachycardia Syndrome (POTS), or Mast Cell Activation Syndrome (MCAS).
**Regulatory framing:** US DSHEA dietary supplement. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

## Key benefits

- 85% of hEDS patients carry MTHFR variants in landmark study
- Regulates MMP-2 activity to protect collagen from degradation
- Critical for BH4 and norepinephrine synthesis for POTS
- Supports HNMT for intracellular histamine clearance

## What it is

The bioactive form of folate that bypasses MTHFR genetic blocks and regulates collagen-destroying enzymes

## Why we include it

Addresses the 85% MTHFR polymorphism prevalence in hEDS patients; essential for ECM protection and neurotransmitter synthesis

## Plain-language summary

Methylfolate is the active, methylated form of folate (vitamin B9) - the form your cells use directly without needing MTHFR enzyme conversion. This matters specifically because 85% of hEDS patients carry MTHFR polymorphisms (a 2024 Tulane study found C677T and/or A1298C variants in 85% of hEDS/HSD patients - more than double the general population rate). Methylfolate bypasses the impaired enzyme entirely. We use the (6S)-5-MTHF calcium salt at 800 mcg in the PM capsule. Methylation supports histamine clearance, catecholamine breakdown, and the dozens of methylation-dependent reactions running every minute in your body.

## Mechanism

Methylfolate bypasses the MTHFR enzyme block to provide active folate. It directly regulates MMP-2 promoter methylation to limit its hyperactivity (which otherwise leads to decorin cleavage and collagen weakness). It is also a mandatory cofactor for BH4 synthesis (essential for norepinephrine) and supports HNMT function to clear intracellular histamine.

## Condition-specific notes

### MCAS (Mast Cell Activation Syndrome)

Supports HNMT function, which clears 50-80% of intracellular histamine. Low overmethylation risk at 800mcg dose.

### hEDS (hypermobile Ehlers-Danlos Syndrome)

Addresses a nearly universal genetic bottleneck in hEDS. Protects collagen by 'silencing' destructive MMP-2 enzymes.

### POTS (Postural Orthostatic Tachycardia Syndrome)

Produces BH4, the cofactor for norepinephrine synthesis. Essential for maintaining vascular tone and heart rate control.

## Why this form

**Selected form:** (6S)-5-MTHF glucosamine salt (Quatrefolic-equivalent spec)

The most stable and bioavailable form of (6S)-5-MTHF. Bypasses metabolic blocks for 100% bioactivity. Superior stability to earlier calcium salts.

**Form comparison:**

| Form | Notes | Selected |
|---|---|---|
| (6S)-5-MTHF glucosamine salt | Stable salt form with ~50% first-pass absorption; the Quatrefolic-brand spec is one verified source, generic-OK | Yes |
| Folic Acid | Inactive synthetic form; requires MTHFR conversion (ineffective for 85% of hEDS) | No |

## Dose protocol

| Step | Dosage | Notes |
|---|---|---|
| Weeks 1-2 | 200 mcg daily | Assess methylation sensitivity |
| Weeks 3-4 | 400 mcg daily | Standard titration |
| Week 5+ | 800 mcg daily | Target maintenance |

**Timeline to effect:** Neurotransmitter benefits within 2-4 weeks; ECM/collagen protection is a long-term mechanism.

## Evidence summary

### hEDS-Specific Genetic Association

Landmark study demonstrating exceptionally high prevalence of MTHFR variants in the hEDS population. Establishes the rationale for using the active form (L-methylfolate) rather than folic acid in this population.

- [1] **Courseault J et al., "MTHFR Polymorphisms in Patients With hEDS".** Design: Single-center prevalence study, Tulane EDS clinic. Finding: 85% of hEDS patients carry MTHFR polymorphisms (double general population prevalence). PMID: 38523329.
- [2] **Courseault J et al., "Folate-dependent hypermobility syndrome: A proposed mechanism".** Design: Mechanism + clinical case proposal. Finding: Low 5-MTHF levels correlate with MMP-2 hyperactivity and increased decorin cleavage in ligaments. PMID: 37095957.

### L-Methylfolate Bioavailability vs Folic Acid

L-5-methyltetrahydrofolate (L-5-MTHF) is the only folate species normally circulating in plasma. Pharmacokinetic comparisons show L-5-MTHF is at least as bioavailable as folic acid, and avoids the unmetabolized-folic-acid concerns that affect supplementation strategies in MTHFR-variant populations.

- [3] **Pietrzik K et al., "Folic acid and L-5-methyltetrahydrofolate: comparison of clinical pharmacokinetics and pharmacodynamics".** Design: Authoritative PK + PD comparison review. Finding: L-5-MTHF at least as effective as folic acid for raising folate status and lowering plasma homocysteine; reduced risk of masking B12-deficiency hematological signs; reduced antifolate-drug interaction. PMID: 20608755.
- [4] **Wright AJA et al., "Comparison of (6S)-5-methyltetrahydrofolic acid v. folic acid as the reference folate in longer-term human dietary intervention studies".** Design: 16-week placebo-controlled RCT in 163 healthy adults. Finding: (6S)-5-MTHF produced equivalent or modestly better plasma + erythrocyte folate response than folic acid; supports use of 5-MTHF as the reference folate in intervention trials. PMID: 19852872.

### Methylated B-Vitamin Stack in POTS

Clinical case evidence for methylated B-vitamin support in COMT and MTHFR-variant POTS patients refractory to standard therapy.

- [5] **Mittal N et al., "Improvement of hyperadrenergic postural orthostatic tachycardia syndrome (POTS) with methylated B vitamins in the setting of a heterozygous COMT Val158Met polymorphism".** Design: BMJ Case Report, POTS patient refractory to conventional treatment. Finding: Patient with COMT Val158Met heterozygosity improved on methylated B vitamins after failing conventional POTS therapy; supports methylation as a clinical layer in autonomic phenotypes. PMID: 34764114.

## Evidence gaps

While the genetic association is Grade A, clinical RCTs testing symptom reversal with methylfolate in hEDS are still pending.

## Safety

**Side effects:** Generally well-tolerated. Anxiety, irritability, or insomnia possible in sensitive overmethylators.

**Interactions:** Antagonized by Methotrexate. May mask B12 deficiency (always paired with B12 in ZebraThrive).

**Cautions:** Always ensure B12 status is optimized alongside folate to prevent neurological masking.

**Excipients to avoid:** Artificial colors, Corn-derived fillers

**Excipients that are safe:** HPMC capsules, Rice flour

## Frequently asked questions

### Why methylfolate instead of folic acid?

Folic acid is the synthetic form most commonly used in fortified foods and basic supplements - it has to be converted through DHFR and then MTHFR to become biologically active. In people with MTHFR variants (85% of hEDS patients), that conversion is impaired, so folic acid can actually accumulate unmethylated and may interfere with normal folate metabolism. Methylfolate is already the active form - it skips the conversion step entirely. For this community, methylfolate is the only defensible folate choice.

### What's the MTHFR connection to hEDS?

A 2024 Tulane Fascia Institute study (Courseault et al.) found that 85% of hEDS patients carry C677T and/or A1298C MTHFR polymorphisms - more than double the general population prevalence. The researchers proposed a 'folate-dependent hypermobility syndrome' model, suggesting that impaired methylation may be a contributing factor to the connective tissue dysfunction in hEDS. MTHFR variants compromise the production of activated folate, which affects everything from neurotransmitter synthesis to histamine clearance to homocysteine handling. Methylfolate bypasses the impaired enzyme directly.

### I've heard some people react badly to methylfolate - should I worry?

It's real. About 5-15% of people experience 'overmethylation' symptoms starting methylated B vitamins - anxiety, agitation, irritability, sleep disruption. MCAS patients can be more sensitive than average. The mechanism is usually a transient rise in neurotransmitter synthesis before clearance catches up. We deliberately dose 800 mcg in the PM capsule - conservative compared to the 15 mg used for depression. If you have a history of overmethylation reactions, start slow and consider taking the PM capsule every other day initially.

### How does methylfolate help with histamine?

Methylfolate doesn't break down histamine directly, but it's foundational to the methylation pathway that does. Your body breaks down histamine through HNMT (in your cells and CNS) and DAO (in your gut). HNMT uses methyl groups from SAMe to inactivate histamine. SAMe is regenerated through the methylfolate-B12 cycle. Inadequate methylfolate means slower SAMe regeneration, which means slower HNMT activity, which means slower histamine clearance - exactly the wrong bottleneck for MCAS. Methylfolate keeps that cycle turning.

## References

[1] Courseault J et al.. (2024). MTHFR Polymorphisms in Patients With hEDS. PMID: 38523329. https://pubmed.ncbi.nlm.nih.gov/38523329/
[2] Courseault J et al.. (2023). Folate-dependent hypermobility syndrome: A proposed mechanism. PMID: 37095957. https://pubmed.ncbi.nlm.nih.gov/37095957/
[3] Pietrzik K et al.. (2010). Folic acid and L-5-methyltetrahydrofolate: comparison of clinical pharmacokinetics and pharmacodynamics. PMID: 20608755. https://pubmed.ncbi.nlm.nih.gov/20608755/
[4] Wright AJA et al.. (2009). Comparison of (6S)-5-methyltetrahydrofolic acid v. folic acid as the reference folate in longer-term human dietary intervention studies. PMID: 19852872. https://pubmed.ncbi.nlm.nih.gov/19852872/
[5] Mittal N et al.. (2021). Improvement of hyperadrenergic postural orthostatic tachycardia syndrome (POTS) with methylated B vitamins in the setting of a heterozygous COMT Val158Met polymorphism. PMID: 34764114. https://pubmed.ncbi.nlm.nih.gov/34764114/